» Articles » PMID: 1540262

Flow Cytometric Characterization of Acute Myeloid Leukemia. Part II. Phenotypic Heterogeneity at Diagnosis

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 1992 Jan 1
PMID 1540262
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The frequency and distribution of aberrant antigen expression are analyzed on bone marrow aspirates from 80 patients with newly diagnosed acute myeloid leukemia (AML) by multidimensional flow cytometry. Parameters examined are the light scatter profile of the leukemic cells and the correlative expression of different combinations of the CD2, 4, 5, 7, 11b, 11c, 13, 14, 15, 16, 33, 34, 38, and HLA-DR antigens. Antigen expression on leukemic cells in bone marrow is described by characteristic antigen expression patterns describing: (i) the percentage of cells expressing the antigen; (ii) the antigen density; and (iii) the distribution of the antigen on the leukemic cells. Typically the non-myeloid antigens are homogeneously expressed by the leukemic cells, whereas the myeloid associated antigen CD11b, CD11c, CD14, and CD15 are heterogeneously expressed. Comparison of the antigenic profiles of 80 bone marrow aspirates revealed an extreme interclonal heterogeneity. Comparison of the antigen expression patterns found in AML patients with the antigen expression in normal bone marrow revealed four patterns of aberrant antigen expression in AML: (i) expression of nonmyeloid antigens (i.e. CD2, CD5, and CD7 were present in 57, 60, and 37% of the patients, respectively); (ii) asynchronous expression of myeloid associated antigens (i.e. co-expression of CD34 and CD15 in 25% of the patients and expression of CD16 on immature myeloid cells in 15% of the cases); (iii) over-expression of myeloid associated antigens (e.g. CD34 in 16% of the cases and CD14 on neutrophilic cells in 19% of all patients); and (iv) absence of expression of myeloid associated antigens (e.g. lack of CD33 in 21% of the cases and lack of both CD11b and CD15 in 6% of all patients. Multidimensional flow cytometric analysis of bone marrow aspirates of AML patients disclosed that the leukemic cells of each AML patient had a unique antigenic profile and could be discriminated from their normal counterparts based on aberrant antigen expression and typical light scatter profiles. The ability to distinguish leukemic cells from normal cells allows the detection of residual leukemic cells during and after chemotherapy.

Citing Articles

A cell-level discriminative neural network model for diagnosis of blood cancers.

Robles E, Jin Y, Smyth P, Scheuermann R, Bui J, Wang H Bioinformatics. 2023; 39(10).

PMID: 37756695 PMC: 10563151. DOI: 10.1093/bioinformatics/btad585.


Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia.

Zhu L, Wang P, Zhang W, Li Q, Xiong J, Li J Cancer Manag Res. 2020; 12:11411-11419.

PMID: 33192098 PMC: 7654521. DOI: 10.2147/CMAR.S260825.


Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.

Pratap S, Zhao Z Cancer Rep (Hoboken). 2020; 3(2):e1222.

PMID: 32671999 PMC: 7941581. DOI: 10.1002/cnr2.1222.


Universal monitoring of minimal residual disease in acute myeloid leukemia.

Coustan-Smith E, Song G, Shurtleff S, Yeoh A, Chng W, Chen S JCI Insight. 2018; 3(9).

PMID: 29720577 PMC: 6012500. DOI: 10.1172/jci.insight.98561.


Methods of Detection of Measurable Residual Disease in AML.

Zhou Y, Wood B Curr Hematol Malig Rep. 2017; 12(6):557-567.

PMID: 29098609 DOI: 10.1007/s11899-017-0419-5.